Obesity as a disease state: A new paradigm for diagnosis and treatment

Clinical cornerstone Pub Date : 2009-01-01 Epub Date: 2009-09-26 DOI:10.1016/S1098-3597(09)80002-1
Louis J. Aronne MD (Clinical Professor of Medicine), Donald S. Nelinson PhD (Chief Scientific Officer), Joseph L. Lillo DO (Assistant Professor of Family Medicine)
{"title":"Obesity as a disease state: A new paradigm for diagnosis and treatment","authors":"Louis J. Aronne MD (Clinical Professor of Medicine),&nbsp;Donald S. Nelinson PhD (Chief Scientific Officer),&nbsp;Joseph L. Lillo DO (Assistant Professor of Family Medicine)","doi":"10.1016/S1098-3597(09)80002-1","DOIUrl":null,"url":null,"abstract":"<div><p>While global prevalence of obesity continues to increase dramatically, treatment options remain less than optimal. The etiology of obesity is multifactorial, ranging from lifestyle choices such as excess food intake and insufficient physical activity, to use of medications that have weight gain as an undesirable side effect. Economic and political determinants of available foodstuffs and even social networks may also contribute to obesity. Successful management of obesity requires the understanding and acceptance of a new paradigm that identifies obesity as a disease—one defined by waist circumference—that requires treatment. Obesity meets all accepted criteria of a medical disease, including a known etiology, recognized signs and symptoms, and a range of structural and functional changes that culminate in pathologic consequences. Excess adipose tissue acts as an endocrine organ to produce excess free fatty acids, as well as tumor necrosis factor-α, interleukin-6, leptin, and plasminogen activator inhibitor-1. These bioactive molecules are associated with hyperinsulinemia, hyperglycemia, insulin resistance, development of diabetes, endothelial damage, and the onset and progression of atherosclerotic lesions. Options for treating obesity include lifestyle modifications (dietary changes, increased physical activity, behavior modification) and, for the morbidly obese, surgery. Lifestyle modification is rarely successful over the long term; therefore, addition of pharmacotherapy should be considered for obese individuals who have difficulty achieving and maintaining weight goals with lifestyle modifications alone. Several weight loss drugs are available for long-term use, with others in various stages of clinical development.</p></div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"9 4","pages":"Pages 9-29"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(09)80002-1","citationCount":"97","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical cornerstone","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1098359709800021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/9/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 97

Abstract

While global prevalence of obesity continues to increase dramatically, treatment options remain less than optimal. The etiology of obesity is multifactorial, ranging from lifestyle choices such as excess food intake and insufficient physical activity, to use of medications that have weight gain as an undesirable side effect. Economic and political determinants of available foodstuffs and even social networks may also contribute to obesity. Successful management of obesity requires the understanding and acceptance of a new paradigm that identifies obesity as a disease—one defined by waist circumference—that requires treatment. Obesity meets all accepted criteria of a medical disease, including a known etiology, recognized signs and symptoms, and a range of structural and functional changes that culminate in pathologic consequences. Excess adipose tissue acts as an endocrine organ to produce excess free fatty acids, as well as tumor necrosis factor-α, interleukin-6, leptin, and plasminogen activator inhibitor-1. These bioactive molecules are associated with hyperinsulinemia, hyperglycemia, insulin resistance, development of diabetes, endothelial damage, and the onset and progression of atherosclerotic lesions. Options for treating obesity include lifestyle modifications (dietary changes, increased physical activity, behavior modification) and, for the morbidly obese, surgery. Lifestyle modification is rarely successful over the long term; therefore, addition of pharmacotherapy should be considered for obese individuals who have difficulty achieving and maintaining weight goals with lifestyle modifications alone. Several weight loss drugs are available for long-term use, with others in various stages of clinical development.

肥胖作为一种疾病状态:诊断和治疗的新范式
虽然全球肥胖患病率继续急剧增加,但治疗方案仍然不够理想。肥胖的病因是多因素的,从生活方式的选择,如过量的食物摄入和身体活动不足,到使用有体重增加的不良副作用的药物。经济和政治因素决定了可获得的食物,甚至社会网络也可能导致肥胖。肥胖的成功管理需要理解和接受一种新的模式,即将肥胖视为一种疾病——由腰围定义——需要治疗。肥胖符合医学疾病的所有公认标准,包括已知的病因,公认的体征和症状,以及最终导致病理后果的一系列结构和功能变化。多余的脂肪组织作为内分泌器官产生多余的游离脂肪酸,以及肿瘤坏死因子-α、白细胞介素-6、瘦素和纤溶酶原激活物抑制剂-1。这些生物活性分子与高胰岛素血症、高血糖、胰岛素抵抗、糖尿病的发展、内皮损伤以及动脉粥样硬化病变的发生和进展有关。治疗肥胖的方法包括改变生活方式(改变饮食、增加体力活动、改变行为),对于病态肥胖患者,则采用手术治疗。改变生活方式很少能长期成功;因此,对于仅通过改变生活方式难以达到和维持体重目标的肥胖个体,应考虑增加药物治疗。有几种减肥药可供长期使用,还有一些处于临床开发的不同阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书